scholarly journals POS-681 ETHICAL CHALLENGES IN PROVIDING KIDNEY REPLACEMENT THERAPY (KRT) FOR PEDIATRIC END STAGE KIDNEY DISEASE: CASE SERIES FROM A REFERRAL CENTRE IN INDIA

2021 ◽  
Vol 6 (4) ◽  
pp. S297-S298
Author(s):  
P. PAIS ◽  
A. Iyengar ◽  
A. Wightman
Keyword(s):  
Kidney Disease ◽  
Replacement Therapy ◽  
Case Series ◽  
Ethical Challenges ◽  
Referral Centre ◽  
End Stage Kidney Disease ◽  
Disease Case ◽  
Kidney Replacement Therapy ◽  
End Stage

scholarly journals Pregnancy and delivery in women treated with renal replacement therapy: A literature review

2021 ◽  
pp. 86-90
Author(s):  
V. Medved ◽  
L. Bulik
Keyword(s):  
Kidney Disease ◽  
Replacement Therapy ◽  
Perinatal Outcomes ◽  
Published Data ◽  
Perinatal Complications ◽  
End Stage Kidney Disease ◽  
Dialysis Therapy ◽  
Pregnancy And Delivery ◽  
Kidney Replacement Therapy ◽  
End Stage

Abstract. The problem of pregnancy and delivery in women with end-stage kidney disease is becoming increasingly important, and the number of such women who are pregnant, receiving kidney replacement therapy, is growing every year. Improvements in dialysis therapy have led to improved obstetric and perinatal outcomes, but the risk of various obstetric and perinatal complications remains extremely high. In this review, we analyzed recently published data on management and outcomes of pregnancy in women with end-stage kidney disease receiving dialysis.

scholarly journals Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey

BMJ ◽  
2019 ◽  
pp. l5873 ◽  
Author(s):  
Aminu K Bello ◽  
Adeera Levin ◽  
Meaghan Lunney ◽  
Mohamed A Osman ◽  
Feng Ye ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Kidney Disease ◽  
Replacement Therapy ◽  
Low Income ◽  
Care Delivery ◽  
End Stage Kidney Disease ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Kidney Replacement Therapy ◽  
End Stage

Abstract Objective To determine the global capacity (availability, accessibility, quality, and affordability) to deliver kidney replacement therapy (dialysis and transplantation) and conservative kidney management. Design International cross sectional survey. Setting International Society of Nephrology (ISN) survey of 182 countries from July to September 2018. Participants Key stakeholders identified by ISN’s national and regional leaders. Main outcome measures Markers of national capacity to deliver core components of kidney replacement therapy and conservative kidney management. Results Responses were received from 160 (87.9%) of 182 countries, comprising 97.8% (7338.5 million of 7501.3 million) of the world’s population. A wide variation was found in capacity and structures for kidney replacement therapy and conservative kidney management—namely, funding mechanisms, health workforce, service delivery, and available technologies. Information on the prevalence of treated end stage kidney disease was available in 91 (42%) of 218 countries worldwide. Estimates varied more than 800-fold from 4 to 3392 per million population. Rwanda was the only low income country to report data on the prevalence of treated disease; 5 (<10%) of 53 African countries reported these data. Of 159 countries, 102 (64%) provided public funding for kidney replacement therapy. Sixty eight (43%) of 159 countries charged no fees at the point of care delivery and 34 (21%) made some charge. Haemodialysis was reported as available in 156 (100%) of 156 countries, peritoneal dialysis in 119 (76%) of 156 countries, and kidney transplantation in 114 (74%) of 155 countries. Dialysis and kidney transplantation were available to more than 50% of patients in only 108 (70%) and 45 (29%) of 154 countries that offered these services, respectively. Conservative kidney management was available in 124 (81%) of 154 countries. Worldwide, the median number of nephrologists was 9.96 per million population, which varied with income level. Conclusions These comprehensive data show the capacity of countries (including low income countries) to provide optimal care for patients with end stage kidney disease. They demonstrate substantial variability in the burden of such disease and capacity for kidney replacement therapy and conservative kidney management, which have implications for policy.

scholarly journals Capturing and monitoring global differences in untreated and treated end-stage kidney disease, kidney replacement therapy modality, and outcomes

2020 ◽  
Vol 10 (1) ◽  
pp. e3-e9 ◽  
Author(s):  
Roberto Pecoits-Filho ◽  
Ikechi G. Okpechi ◽  
Jo-Ann Donner ◽  
David C.H. Harris ◽  
Harith M. Aljubori ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Replacement Therapy ◽  
End Stage Kidney Disease ◽  
Kidney Replacement Therapy ◽  
End Stage

scholarly journals Global Epidemiology of End-Stage Kidney Disease and Disparities in Kidney Replacement Therapy

2021 ◽  
pp. 1-10
Author(s):  
John S. Thurlow ◽  
Megha Joshi ◽  
Guofen Yan ◽  
Keith C. Norris ◽  
Lawrence Y. Agodoa ◽  
...  
Keyword(s):  
Health Care ◽  
Kidney Disease ◽  
Replacement Therapy ◽  
Practice Patterns ◽  
Care Delivery ◽  
End Stage Kidney Disease ◽  
Global Epidemiology ◽  
Kidney Replacement Therapy ◽  
End Stage ◽  
Population Demographic

Background: The global epidemiology of end-stage kidney disease (ESKD) reflects each nation’s unique genetic, environmental, lifestyle, and sociodemographic characteristics. The response to ESKD, particularly regarding kidney replacement therapy (KRT), depends on local disease burden, culture, and socioeconomics. Here, we explore geographic variation and global trends in ESKD incidence and prevalence and examine variations in KRT modality, practice patterns, and mortality. We conclude with a discussion on disparities in access to KRT and strategies to reduce ESKD global burden and to improve access to treatment in low- and middle-income countries (LMICs). Summary: From 2003 to 2016, incidence rates of treated ESKD were relatively stable in many higher income countries but rose substantially predominantly in East and Southeast Asia. The prevalence of treated ESKD has increased worldwide, likely due to improving ESKD survival, population demographic shifts, higher prevalence of ESKD risk factors, and increasing KRT access in countries with growing economies. Unadjusted 5-year survival of ESKD patients on KRT was 41% in the USA, 48% in Europe, and 60% in Japan. Dialysis is the predominant KRT in most countries, with hemodialysis being the most common modality. Variations in dialysis practice patterns account for some of the differences in survival outcomes globally. Worldwide, there is a greater prevalence of KRT at higher income levels, and the number of people who die prematurely because of lack of KRT access is estimated at up to 3 times higher than the number who receive treatment. Key Messages: Many people worldwide in need of KRT as a life-sustaining treatment do not receive it, mostly in LMICs where health care resources are severely limited. This large treatment gap demands a focus on population-based prevention strategies and development of affordable and cost-effective KRT. Achieving global equity in KRT access will require concerted efforts in advocating effective public policy, health care delivery, workforce capacity, education, research, and support from the government, private sector, nongovernmental, and professional organizations.

scholarly journals Protection of Residual Renal Function and Nutritional Treatment: First Step Strategy for Reduction of Uremic Toxins in End-Stage Kidney Disease Patients

Toxins ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 289
Author(s):  
Adamasco Cupisti ◽  
Piergiorgio Bolasco ◽  
Claudia D’Alessandro ◽  
Domenico Giannese ◽  
Alice Sabatino ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Residual Renal Function ◽  
The Body ◽  
Uremic Toxins ◽  
End Stage Kidney Disease ◽  
Waste Products ◽  
Hemodialysis Treatment ◽  
Life Saving ◽  
Kidney Replacement Therapy ◽  
End Stage

The retention of uremic toxins and their pathological effects occurs in the advanced phases of chronic kidney disease (CKD), mainly in stage 5, when the implementation of conventional thrice-weekly hemodialysis is the prevalent and life-saving treatment. However, the start of hemodialysis is associated with both an acceleration of the loss of residual kidney function (RKF) and the shift to an increased intake of proteins, which are precursors of uremic toxins. In this phase, hemodialysis treatment is the only way to remove toxins from the body, but it can be largely inefficient in the case of high molecular weight and/or protein-bound molecules. Instead, even very low levels of RKF are crucial for uremic toxins excretion, which in most cases are protein-derived waste products generated by the intestinal microbiota. Protection of RKF can be obtained even in patients with end-stage kidney disease (ESKD) by a gradual and soft shift to kidney replacement therapy (KRT), for example by combining a once-a-week hemodialysis program with a low or very low-protein diet on the extra-dialysis days. This approach could represent a tailored strategy aimed at limiting the retention of both inorganic and organic toxins. In this paper, we discuss the combination of upstream (i.e., reduced production) and downstream (i.e., increased removal) strategies to reduce the concentration of uremic toxins in patients with ESKD during the transition phase from pure conservative management to full hemodialysis treatment.

Sign in / Sign up

Export Citation Format

Share Document